 Phio invites investors, advisors and analysts with an interest in the life sciences sector to attend this virtual eventR. Todd Plott, M.D., Chief Medical Officer, Epiphany Dermatology will join Robert Bitterman, Phio

<p><b> Phio invites investors, advisors and analysts with an interest in the life sciences sector to attend this virtual event</b></p><p><b>R. Todd Plott, M.D., Chief Medical Officer, Epiphany Dermatology will join Robert Bitterman, Phio Pharmaceuticals and Steven Saltzstein, Force Family Office</b></p><p>King of Prussia, Pennsylvania--(Newsfile Corp. - April 13, 2026) - Phio Pharmaceuticals Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/PHIO">PHIO</a>) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL<sup>&#174;</sup> gene silencing technology to eliminate cancer. Phio announced today that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will participate in a fireside chat with Steven Saltzstein, CEO, Force Family Office. Joining them will be Dr. R. Todd Plott, Chief Medical Officer, Epiphany Dermatology and former consultant to the FDA who will provide additional insight on PH-762, an INTASYL compound, that silences the PD-1 gene implicated in various forms of skin cancer.</p><p>"We are excited to hold this fireside chat with Force Family Office. Dr. Plott will discuss why the INTASYL siRNA program represents a differentiated approach to immuno-oncology," said Robert Bitterman, CEO and Chairman of Phio Pharmaceuticals.</p><p><b>DATE:  Wednesday April 15, 2026</b></p><p><b>TIME:   12 PM EDT</b></p><p><b>REGISTRATION LINK:  </b><a href="https://api.newsfilecorp.com/redirect/5WbG4iWgjm"><b>PHIO Pharma - Force Family Office</b></a></p><p><b>Recent Company Highlights</b><br />Phio's lead clinical candidate, PH-762, is being evaluated as an intratumoral therapy in cutaneous squamous cell carcinoma (cSCC), melanoma and Merkel cell carcinoma. In its Phase 1b trial, Phio has reported that 22 patients completed treatment across five dose-escalation cohorts, with no dose-limiting toxicities or serious adverse events. The Company has also reported a pathological response rate in cSCC across all dosing cohorts of approximately 65%, including an 85% pathological response (6 of 7 patients) in the highest-dose cohort.</p><p>Phio has indicated that FDA engagement regarding next-stage clinical development is targeted for the second quarter of 2026 and has reported cash and cash equivalents projected to sustain operations into the first half of 2027.</p><p><b>About Phio Pharmaceuticals Corp.</b> <br />Phio Pharmaceuticals Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/PHIO">PHIO</a>) is a clinical-stage siRNA biopharmaceutical company advancing its INTASYL<sup>&#174;</sup> gene silencing technology focused on immuno-oncology therapeutics. Phio's INTASYL compounds are designed to enhance the body's immune cells to more effectively kill cancer cells. Phio's lead clinical program is an INTASYL compound, PH-762, that silences the PD-1 gene implicated in various forms of skin cancer. The Phase 1b trial (NCT# 06014086) is evaluating PH-762 for the treatment of cutaneous squamous cell carcinoma, melanoma and Merkel cell carcinoma. PH-762 is a potential non-surgical treatment for skin cancers.</p><p>For additional information, visit the Company's website, <a href="https://api.newsfilecorp.com/redirect/LqreKhGBeB">www.phiopharma.com</a>.  </p><p><b>Forward-Looking Statements</b> <br /><i>This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "intends," "believes," "anticipates," "indicates," "plans," "expects," "suggests," "may," "would," "should," "potential," "designed to," "will," "ongoing," "estimate," "forecast," "target," "predict," "could" and similar references, although not all forward-looking statements contain these words. These statements, which include statements regarding the anticipated benefits of our INTASYL&#8482; RNAi platform, the results from our ongoing clinical trials, our expectations that our cash runway will extend into the first half of 2027, our expectations regarding timing of FDA submissions intended to propose and seek guidance for next steps in clinical study design for PH-762, details regarding our planned non-clinical toxicology study, and our ability to support ongoing clinical development, operational requirements and strategic initiatives with the capital we currently have on hand, are based only on our current beliefs, expectations and assumptions and are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements as a result of a number of important factors, including, but not limited to, the impact to our business and operations by inflationary pressures, rising interest rates, recession fears, the development of our product candidates, results from our preclinical and clinical activities, our ability to execute on business strategies, our ability to develop our product candidates with collaboration partners, and the success of any such collaborations, the timeline and duration for advancing our product candidates into clinical development, the timing or likelihood of regulatory filings and approvals, the success of our efforts to commercialize our product candidates if approved, our ability to manufacture and supply our product candidates for clinical activities, and for commercial use if approved, the scope of protection we are able to establish and maintain for intellectual property rights covering our technology platform, our ability to obtain future financing, market and other conditions and those risks identified in our Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption "Risk Factors" and in other filings the Company periodically makes with the SEC. Readers are urged to review these risk factors and to not act in reliance on any forward-looking statements, as actual results may differ from those contemplated by our forward-looking statements. Phio does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release, except as required by law.</i></p><p><b>About FORCE Family Office</b><br />FORCE works with Family Offices, Ultra High Net Worth Individuals, their Foundations, and Endowments by introducing them to leaders of privately held businesses at the capital acquisition stage and public companies looking for open market buyers. FORCE is constantly bringing unique opportunities and information to their community of investors. In addition, their elite peer-to-peer community brings family offices, UHNW individuals, endowments and foundations together, facilitating co-investment opportunities, information sharing, philanthropy, and networking.</p><div id="contactInfo"><p><b>CONTACTS:</b></p><p><b>Phio Pharmaceuticals Corp.</b><br />Jennifer Phillips: <a href="mailto:jphillips@phiopharma.com" target="_blank">jphillips@phiopharma.com</a> <br />Corporate Affairs </p><p><b>FORCE Family Office</b><br />Harvey Briggs<br />608-361-8092<br /><a href="https://api.newsfilecorp.com/redirect/oPDE0fBVQP">forcefamilyoffice.com</a></p></div><p id="corporateNewsLogoContainer"><img src="https://images.newsfilecorp.com/files/10407/292112_584b9fef541bb891_logo.jpg" id="corporateNewsLogo" alt="Corporate Logo" /></p><p id="corporateLinkBack">To view the source version of this press release, please visit <a href="https://api.newsfilecorp.com/redirect/OA417T2yeA">https://www.newsfilecorp.com/release/292112</a></p><p><img src="https://api.newsfilecorp.com/newsinfo/292112/197" alt="" /></p>

PHIO

Phio Pharmaceuticals Announces "Nobel Prize Winning Science Takes on Skin Cancer" in a Fireside Chat with Force Family Office on Wednesday, April 15, 2026

Phio Pharmaceuticals to Present PH-762 Insights at Upcoming Investor Event

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>Phio invites investors, advisors and analysts with an interest in the life sciences sector to attend this virtual eventR. Todd Plott, M.D., Chief Medical Officer, Epiphany Dermatology will join Robert Bitterman, Phio</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Phio Pharmaceuticals is holding a virtual event to discuss its lead candidate, PH-762, on April 15, 2026. The company recently reported a 65% pathological response rate in Phase 1b trials, bolstering investor confidence leading up to FDA engagement planned for the second quarter of 2026.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Phio Pharmaceuticals hosts a virtual event on April 15, 2026.</li><li>CEO Robert Bitterman and Dr. R. Todd Plott will discuss PH-762&#039;s efficacy.</li><li>PH-762 shows a 65% pathological response rate in clinical trials.</li><li>FDA engagement for PH-762&#039;s next stage is targeted for Q2 2026.</li><li>Phio has sufficient cash to sustain operations into H1 2027.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Epiphany Dermatology</strong>: Their CMO will provide expert insights at the upcoming event.</li><li><strong>Force Family Office</strong>: They facilitate investment opportunities in life sciences sectors.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>This news falls under &#039;Corporate Developments&#039; as it highlights a key investor event and significant trial results for PH-762, impacting perceptions of the company’s value and future prospects.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>PH-762&#039;s promising trial results could attract new investment.</li><li>FDA engagement for clinical development will be a key market catalyst.</li><li>Positive reception at the investor event could boost share prices.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>PH-762 shows a 65% pathological response rate in skin cancer treatments.</li><li>The virtual event is scheduled for April 15, 2026, at 12 PM EDT.</li><li>Phio&#039;s cash reserves are projected to support operations until H1 2027.</li><li>22 patients completed treatment in the Phase 1b trial without serious adverse events.</li><li>The highest-dose cohort achieved an 85% pathological response.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Considering the upcoming investor event and positive trial results, PHIO is likely to see a price increase in the near term.</p>
  </section>
</section>


<p><b> Phio invites investors, advisors and analysts with an interest in the life sciences sector to attend this virtual event</b></p><p><b>R. Todd Plott, M.D., Chief Medical Officer, Epiphany Dermatology will join Robert Bitterman, Phio Pharmaceuticals and Steven Saltzstein, Force Family Office</b></p><p>King of Prussia, Pennsylvania--(Newsfile Corp. - April 13, 2026) - Phio Pharmaceuticals Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/PHIO">PHIO</a>) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL<sup>&#174;</sup> gene silencing technology to eliminate cancer. Phio announced today that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will participate in a fireside chat with Steven Saltzstein, CEO, Force Family Office. Joining them will be Dr. R. Todd Plott, Chief Medical Officer, Epiphany Dermatology and former consultant to the FDA who will provide additional insight on PH-762, an INTASYL compound, that silences the PD-1 gene implicated in various forms of skin cancer.</p><p>"We are excited to hold this fireside chat with Force Family Office. Dr. Plott will discuss why the INTASYL siRNA program represents a differentiated approach to immuno-oncology," said Robert Bitterman, CEO and Chairman of Phio Pharmaceuticals.</p><p><b>DATE:  Wednesday April 15, 2026</b></p><p><b>TIME:   12 PM EDT</b></p><p><b>REGISTRATION LINK:  </b><a href="https://api.newsfilecorp.com/redirect/5WbG4iWgjm"><b>PHIO Pharma - Force Family Office</b></a></p><p><b>Recent Company Highlights</b><br />Phio's lead clinical candidate, PH-762, is being evaluated as an intratumoral therapy in cutaneous squamous cell carcinoma (cSCC), melanoma and Merkel cell carcinoma. In its Phase 1b trial, Phio has reported that 22 patients completed treatment across five dose-escalation cohorts, with no dose-limiting toxicities or serious adverse events. The Company has also reported a pathological response rate in cSCC across all dosing cohorts of approximately 65%, including an 85% pathological response (6 of 7 patients) in the highest-dose cohort.</p><p>Phio has indicated that FDA engagement regarding next-stage clinical development is targeted for the second quarter of 2026 and has reported cash and cash equivalents projected to sustain operations into the first half of 2027.</p><p><b>About Phio Pharmaceuticals Corp.</b> <br />Phio Pharmaceuticals Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/PHIO">PHIO</a>) is a clinical-stage siRNA biopharmaceutical company advancing its INTASYL<sup>&#174;</sup> gene silencing technology focused on immuno-oncology therapeutics. Phio's INTASYL compounds are designed to enhance the body's immune cells to more effectively kill cancer cells. Phio's lead clinical program is an INTASYL compound, PH-762, that silences the PD-1 gene implicated in various forms of skin cancer. The Phase 1b trial (NCT# 06014086) is evaluating PH-762 for the treatment of cutaneous squamous cell carcinoma, melanoma and Merkel cell carcinoma. PH-762 is a potential non-surgical treatment for skin cancers.</p><p>For additional information, visit the Company's website, <a href="https://api.newsfilecorp.com/redirect/LqreKhGBeB">www.phiopharma.com</a>.  </p><p><b>Forward-Looking Statements</b> <br /><i>This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "intends," "believes," "anticipates," "indicates," "plans," "expects," "suggests," "may," "would," "should," "potential," "designed to," "will," "ongoing," "estimate," "forecast," "target," "predict," "could" and similar references, although not all forward-looking statements contain these words. These statements, which include statements regarding the anticipated benefits of our INTASYL&#8482; RNAi platform, the results from our ongoing clinical trials, our expectations that our cash runway will extend into the first half of 2027, our expectations regarding timing of FDA submissions intended to propose and seek guidance for next steps in clinical study design for PH-762, details regarding our planned non-clinical toxicology study, and our ability to support ongoing clinical development, operational requirements and strategic initiatives with the capital we currently have on hand, are based only on our current beliefs, expectations and assumptions and are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements as a result of a number of important factors, including, but not limited to, the impact to our business and operations by inflationary pressures, rising interest rates, recession fears, the development of our product candidates, results from our preclinical and clinical activities, our ability to execute on business strategies, our ability to develop our product candidates with collaboration partners, and the success of any such collaborations, the timeline and duration for advancing our product candidates into clinical development, the timing or likelihood of regulatory filings and approvals, the success of our efforts to commercialize our product candidates if approved, our ability to manufacture and supply our product candidates for clinical activities, and for commercial use if approved, the scope of protection we are able to establish and maintain for intellectual property rights covering our technology platform, our ability to obtain future financing, market and other conditions and those risks identified in our Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption "Risk Factors" and in other filings the Company periodically makes with the SEC. Readers are urged to review these risk factors and to not act in reliance on any forward-looking statements, as actual results may differ from those contemplated by our forward-looking statements. Phio does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release, except as required by law.</i></p><p><b>About FORCE Family Office</b><br />FORCE works with Family Offices, Ultra High Net Worth Individuals, their Foundations, and Endowments by introducing them to leaders of privately held businesses at the capital acquisition stage and public companies looking for open market buyers. FORCE is constantly bringing unique opportunities and information to their community of investors. In addition, their elite peer-to-peer community brings family offices, UHNW individuals, endowments and foundations together, facilitating co-investment opportunities, information sharing, philanthropy, and networking.</p><div id="contactInfo"><p><b>CONTACTS:</b></p><p><b>Phio Pharmaceuticals Corp.</b><br />Jennifer Phillips: <a href="mailto:jphillips@phiopharma.com" target="_blank">jphillips@phiopharma.com</a> <br />Corporate Affairs </p><p><b>FORCE Family Office</b><br />Harvey Briggs<br />608-361-8092<br /><a href="https://api.newsfilecorp.com/redirect/oPDE0fBVQP">forcefamilyoffice.com</a></p></div><p id="corporateNewsLogoContainer"><img src="https://images.newsfilecorp.com/files/10407/292112_584b9fef541bb891_logo.jpg" id="corporateNewsLogo" alt="Corporate Logo" /></p><p id="corporateLinkBack">To view the source version of this press release, please visit <a href="https://api.newsfilecorp.com/redirect/OA417T2yeA">https://www.newsfilecorp.com/release/292112</a></p><p><img src="https://api.newsfilecorp.com/newsinfo/292112/197" alt="" /></p>

Phio Pharmaceuticals is holding a virtual event to discuss its lead candidate, PH-762, on April 15, 2026. The company recently reported a 65% pathological response rate in Phase 1b trials, bolstering investor confidence leading up to FDA engagement planned for the second quarter of 2026.

Phio Pharmaceuticals Announces "Nobel Prize Winning Science Takes on Skin Cancer" in a Fireside Chat with Force Family Office on Wednesday, April 15, 2026

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News